BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23971691)

  • 1. Therapeutic approach for neuronal disease by regulating renin-angiotensin system.
    Ohshima K; Mogi M; Horiuchi M
    Curr Hypertens Rev; 2013 May; 9(2):99-107. PubMed ID: 23971691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats.
    Yang R; Yang B; Wen Y; Fang F; Cui S; Lin G; Sun Z; Wang R; Dai Y
    J Sex Med; 2009 Mar; 6(3):696-707. PubMed ID: 19175863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.
    Almeida-Santos AF; Kangussu LM; Campagnole-Santos MJ
    Protein Pept Lett; 2017 Nov; 24(9):841-853. PubMed ID: 28828974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence.
    Fouda AY; Artham S; El-Remessy AB; Fagan SC
    Clin Sci (Lond); 2016 Feb; 130(4):221-38. PubMed ID: 26769658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibition: a new modality for hypertension management.
    Siragy HM
    Curr Hypertens Rep; 2007 Aug; 9(4):291-4. PubMed ID: 17686379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.
    Steckelings UM; Rompe F; Kaschina E; Unger T
    Fundam Clin Pharmacol; 2009 Dec; 23(6):693-703. PubMed ID: 19817870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic role of Renin-Angiotensin System blockers in obesity- related renal disorders.
    Santos SH; Simões e Silva AC
    Curr Clin Pharmacol; 2014 Feb; 9(1):2-9. PubMed ID: 23270435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
    Vaněčková I; Kujal P; Husková Z; Vaňourková Z; Vernerová Z; Certíková Chábová V; Skaroupková P; Kramer HJ; Tesař V; Červenka L
    Kidney Blood Press Res; 2012; 35(5):382-92. PubMed ID: 22487948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensins in Alzheimer's disease - friend or foe?
    Kehoe PG; Miners S; Love S
    Trends Neurosci; 2009 Dec; 32(12):619-28. PubMed ID: 19796831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
    Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
    J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
    Scott BB; McGeehan GM; Harrison RK
    Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.